NVDA Q3 Earnings Alert: Why our AI stock picker is still holding Nvidia stockRead More

Novavax Soars as Covid Shot Candidate Gets Israel Order  

Published 01/31/2022, 11:40 PM
© Reuters
NVAX
-

By Dhirendra Tripathi

Investing.com – Novavax stock (NASDAQ:NVAX) surged 11% Monday after it said it won a contract from the Israel government for its proposed Covid-19 vaccine.

Under the advance purchase agreement, Novavax will provide an initial 5 million doses of its protein-based vaccine with an option for Israel to purchase an additional 5 million. The company will work with the Ministry of Health to obtain the necessary authorizations and finalize plans for distribution in the country pending regulatory approval.

Israel was among the first few countries to have approved a booster following two shots of the vaccine. The country is also offering anyone over 60 a chance to get a fourth shot.

The contract marks a big win for Novavax which is late to the market with its Covid vaccine because of manufacturing issues, all of which it resolved. The vaccine has approvals from the E.U., the WHO, and in several countries. It expects to submit its application for emergency use authorization with the U.S. Food and Drug Administration in some time.

India’s Serum Institute is the contracted party to make the vaccines. Serum is also making AstraZeneca’s Covid-19 shots.

The protein-based vaccine by Novavax has shown to be more than 90% effective, including against a variety of concerning coronavirus variants. The company plans to begin commercial manufacturing of a vaccine tailored to the highly transmissible Omicron coronavirus variant this month, according to a previous report by Reuters.

 

 

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.